ID   LANN_STRMG              Reviewed;          63 AA.
AC   O68586;
DT   23-JAN-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1998, sequence version 1.
DT   02-DEC-2020, entry version 61.
DE   RecName: Full=Lantibiotic mutacin-1140;
DE   AltName: Full=Mutacin III;
DE   Flags: Precursor;
GN   Name=lanA; Synonyms=mutA;
OS   Streptococcus mutans.
OC   Bacteria; Firmicutes; Bacilli; Lactobacillales; Streptococcaceae;
OC   Streptococcus.
OX   NCBI_TaxID=1309;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=JH1005;
RX   PubMed=9596742; DOI=10.1128/iai.66.6.2743-2749.1998;
RA   Hillman J.D., Novak J., Sagura E., Gutierrez J.A., Brooks T.A.,
RA   Crowley P.J., Hess M., Azizi A., Leung K.-P., Cvitkovitch D.,
RA   Bleiweis A.S.;
RT   "Genetic and biochemical analysis of mutacin 1140, a lantibiotic from
RT   Streptococcus mutans.";
RL   Infect. Immun. 66:2743-2749(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RC   STRAIN=UA787;
RX   PubMed=10473390; DOI=10.1128/aem.65.9.3880-3887.1999;
RA   Qi F., Chen P., Caufield P.W.;
RT   "Purification of mutacin III from group III Streptococcus mutans UA787 and
RT   genetic analyses of mutacin III biosynthesis genes.";
RL   Appl. Environ. Microbiol. 65:3880-3887(1999).
RN   [3]
RP   PROTEIN SEQUENCE OF 42-63, IDENTIFICATION BY MASS SPECTROMETRY, STRUCTURE
RP   BY NMR, DEHYDRATION AT SER-46 AND THR-55, AND LANTHIONINE CROSS-LINKS.
RX   PubMed=11082191; DOI=10.1046/j.1432-1033.2000.01777.x;
RA   Smith L., Novak J., Rocca J., McClung S., Hillman J.D., Edison A.S.;
RT   "Covalent structure of mutacin 1140 and a novel method for the rapid
RT   identification of lantibiotics.";
RL   Eur. J. Biochem. 267:6810-6816(2000).
CC   -!- FUNCTION: Lanthionine-containing peptide antibiotic (lantibiotic)
CC       active on Gram-positive bacteria. The bactericidal activity of
CC       lantibiotics is based on depolarization of energized bacterial
CC       cytoplasmic membranes, initiated by the formation of aqueous
CC       transmembrane pores.
CC   -!- PTM: Maturation of lantibiotics involves the enzymatic conversion of
CC       Thr, and Ser into dehydrated AA and the formation of thioether bonds
CC       with cysteine. The C-terminal lanthionine undergoes decarboxylation.
CC       This is followed by membrane translocation and cleavage of the modified
CC       precursor.
CC   -!- PTM: The structure of the 2,3-didehydrobutyrine is not discussed in
CC       PubMed:11082191.
CC   -!- SIMILARITY: Belongs to the type A lantibiotic family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF051560; AAC18827.1; -; Genomic_DNA.
DR   EMBL; AF154675; AAD56142.1; -; Genomic_DNA.
DR   RefSeq; WP_002268802.1; NZ_LTAK01000001.1.
DR   TCDB; 1.C.20.1.8; the nisin (nisin) family.
DR   GO; GO:0005576; C:extracellular region; IEA:InterPro.
DR   GO; GO:0005102; F:signaling receptor binding; IEA:UniProtKB-KW.
DR   GO; GO:0019835; P:cytolysis; IEA:UniProtKB-KW.
DR   GO; GO:0042742; P:defense response to bacterium; IEA:UniProtKB-KW.
DR   InterPro; IPR006079; Lantibiotic_typ-A_Bacillales.
DR   Pfam; PF02052; Gallidermin; 1.
DR   PRINTS; PR00323; GALLIDERMIN.
DR   TIGRFAMs; TIGR03731; lantibio_gallid; 1.
PE   1: Evidence at protein level;
KW   Antibiotic; Antimicrobial; Bacteriocin; D-amino acid;
KW   Direct protein sequencing; Lantibiotic; Thioether bond.
FT   PROPEP          1..41
FT                   /evidence="ECO:0000269|PubMed:11082191"
FT                   /id="PRO_0000017130"
FT   PEPTIDE         42..63
FT                   /note="Lantibiotic mutacin-1140"
FT                   /id="PRO_0000017131"
FT   MOD_RES         46
FT                   /note="2,3-didehydroalanine (Ser)"
FT                   /evidence="ECO:0000269|PubMed:11082191"
FT   MOD_RES         55
FT                   /note="2,3-didehydrobutyrine"
FT                   /evidence="ECO:0000269|PubMed:11082191"
FT   CROSSLNK        44..48
FT                   /note="Lanthionine (Ser-Cys)"
FT                   /evidence="ECO:0000269|PubMed:11082191"
FT   CROSSLNK        49..52
FT                   /note="Beta-methyllanthionine (Thr-Cys)"
FT                   /evidence="ECO:0000269|PubMed:11082191"
FT   CROSSLNK        57..62
FT                   /note="Lanthionine (Ser-Cys)"
FT                   /evidence="ECO:0000269|PubMed:11082191"
FT   CROSSLNK        60..63
FT                   /note="S-(2-aminovinyl)-D-cysteine (Ser-Cys)"
FT                   /evidence="ECO:0000269|PubMed:11082191"
SQ   SEQUENCE   63 AA;  6968 MW;  ED9BC73771758489 CRC64;
     MSNTQLLEVL GTETFDVQED LFAFDTTDTT IVASNDDPDT RFKSWSLCTP GCARTGSFNS
     YCC
//
